Paxlovid is registered in the Netherlands for the group of high-risk patients, to reduce the chance of a more serious acute course of a COVID infection (hospitalization, ICU admission or death) in the event of (re)infection. At this time, there is insufficient scientific evidence that starting Paxlovid in people with post-COVID, at the time of (re)infection, leads to a less serious course or relapse. That is why post-COVID is not included in the group of high-risk patients who have an indication to receive this at the time of (re)infection.
There is also no scientific basis for using Paxlovid for the treatment of post-COVID, although this is currently being investigated. In the Netherlands, there is currently no possibility for people with post-COVID to qualify for Paxlovid on an individual basis, with the help of a general practitioner or another doctor.
